Latest Aura Biosciences News & Updates

See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Aura Biosciences

Biotechnology company developing targeted therapies for solid tumors

aurabiosciences.com
Headquarters
Boston, United States
Founded year
2009
Company type
Public company
Number of employees
125–200

Last updated

Latest news about Aura Biosciences

In short: Aura Biosciences completed Phase 3 CoMpass trial enrollment, raised $299 million, and appointed Natalie Holles as CEO to lead regulatory filings.

Company announcements

Aura Biosciences

Aura Biosciences announces $260 million public offering pricing

The offering includes 39,591,000 common stock shares at $6.00 each and pre-funded warrants. Proceeds will fund clinical programs and repurchase shares from Matrix Capital. Expected to close May 5, 2026.

Unlock all announcements with a

Media coverage

Yahoo Finance

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing...

Unlock all articles with a

Never miss news about Aura Biosciences

Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aura Biosciences competitors & trending companies

Browse news for competitors to Aura Biosciences and other trending companies.